Mercury Bio

About

Mercury Bio is an innovative pharmaceutical company based in Santa Fe, New Mexico, pioneering next-generation biomolecular drug delivery solutions through their proprietary chimeric extracellular vesicle (yEV™) technology platform. The company specializes in developing targeted RNA and small-molecule drug delivery systems designed to overcome traditional obstacles in pharmaceutical development. Mercury Bio's cutting-edge platform enables highly specific cell targeting without triggering immune reactions, offering multiple delivery routes including injectable, aerosol, and probiotic applications. Their scalable, low-cost production platform has the potential to significantly reduce side effects while increasing drug potency, making treatments more effective and accessible. The company leverages deep scientific expertise across molecular biophysics, molecular biology, microbial genetics, biochemistry, and computational science to advance their innovative drug delivery solutions. Mercury Bio maintains strategic research partnerships with prestigious institutions including Los Alamos National Laboratory, the National Center for Genome Resources, New Mexico Consortium, and Himed LLC. With their focus on addressing critical challenges in drug delivery, Mercury Bio is positioned to accelerate pharmaceutical development timelines and improve therapeutic outcomes. Their unique yEV™ technology represents a significant advancement in precision medicine, offering pharmaceutical manufacturers and researchers a powerful tool for developing more effective treatments with reduced adverse effects.